Clinical Trial Update: To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS [Phase 3]

View source ↗

Summary

Phase 3 trial assessing arbaclofen ER tablets vs placebo on sperm parameters in male MS patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Arbaclofen ER (arbaclofen ER)

Snippet

Sponsor: RVL Pharmaceuticals, Inc. | Conditions: Multiple Sclerosis, Sperm | Phase 3 | Status: WITHDRAWN